Is heart failure the missing 800 pound gorilla in diabetes trials? That's the argument proposed by a group of prominent cardiovascular and diabetes researchers. It was long believed that by virtue of their glucose-lowering properties diabetes drugs would confer substantial cardiovascular benefits. Now, however, that belief is no longer widely held [...]
In middle school Michael Shelver went through a rebellious phase. He stopped caring about his body and started having fun. For Shelver rebellion had a cost, as his fun landed him in the hospital. @@contacted, name checked@@
Diagnoses of Type 1 diabetes in Philadelphia children younger than 5 jumped 70 percent between 1985 and 2004, according to the Philadelphia Pediatric Diabetes Registry. New data show such cases continued to climb between 2005 and 2009.
Measuring blood sugar when you have diabetes usually involves pricking your finger and using a glucose monitor for the test. While this approach can give people with diabetes vital information about whether they need to take insulin or eat something sugary, it is nevertheless painful and inconvenient. ...
Caisson Biotech, which signed on with Novo Nordisk in 2012 for the development of drugs using Caisson's delivery platform HEPtune, expanded the scope of the deal to cover specific indications, including its approach to insulin delivery.
(PRWEB) March 08, 2014 Atlantic Peptides (http://www.atlanticpeptides.com/), a custom peptide manufacturer that works with scientific research laboratories and academic institutions from around the world, announces that it will now offer Glucagon as one of its amino acid peptides. The hormones contained in the 29-chain amino acid counter the regulatory functions of insulin, and have been aggressively researched throughout the decade as a potential treatment of diabetes.